• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Hauser Bradley

    6/20/24 8:34:51 PM ET
    $AMIX
    Medical/Dental Instruments
    Health Care
    Get the next $AMIX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Hauser Bradley

    (Last) (First) (Middle)
    C/O AUTONOMIX MEDICAL, INC.
    21 WATERWAY AVENUE, SUITE 300

    (Street)
    THE WOODLANDS TX 77380

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/17/2024
    3. Issuer Name and Ticker or Trading Symbol
    Autonomix Medical, Inc. [ AMIX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CEO and President
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Trent Smith, Attorney-in-Fact for Brad Hauser 06/20/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AMIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMIX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase ("PoC 2") of Proof-of-Concept Human Clinical Study

      Expansion of study into additional indications doubles the potential addressable market beyond pancreatic cancer pain PoC 2 phase builds on early success and positive results demonstrated in PoC 1 in patients with severe pancreatic cancer pain, supporting multi-indication growth strategy THE WOODLANDS, TX, June 30, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the first patient has been enrolled and treated in the follow-on phase to its proof-of-concept human clinical tr

      6/30/25 8:30:00 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology

      Patent supports the Company's broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix's growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,279,889 B2 (the ‘889 patent) titled, "Systems and Methods for Neurological Traffic and/or Receptor F

      6/27/25 8:00:00 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain

      Follow-on study ("PoC 2") builds on initial success in pancreatic cancer pain  Ethics committee authorization supports platform expansion into visceral cancer pain for proprietary ablation technology Expansion supports Autonomix's strategy to build long-term value through multi-indication growth Patient enrollment expected to begin in June 2025 THE WOODLANDS, TX, June 05, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has received Ethics Committee authorization

      6/5/25 8:45:00 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care

    $AMIX
    SEC Filings

    See more
    • SEC Form 10-K filed by Autonomix Medical Inc.

      10-K - Autonomix Medical, Inc. (0001617867) (Filer)

      5/29/25 5:00:54 PM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • Autonomix Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Autonomix Medical, Inc. (0001617867) (Filer)

      4/30/25 8:15:11 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Autonomix Medical Inc.

      EFFECT - Autonomix Medical, Inc. (0001617867) (Filer)

      3/12/25 12:15:04 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care

    $AMIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Robins David Andrew

      4 - Autonomix Medical, Inc. (0001617867) (Issuer)

      7/26/24 4:06:58 PM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Bisson Lori

      4 - Autonomix Medical, Inc. (0001617867) (Issuer)

      6/24/24 5:10:04 PM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Klemp Walter V

      4 - Autonomix Medical, Inc. (0001617867) (Issuer)

      6/24/24 5:09:31 PM ET
      $AMIX
      Medical/Dental Instruments
      Health Care

    $AMIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

      Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives in anticipation of the FDA approval process for first-in-class catheter-based sensing technology Company remains on track to submit an Investigational Device Exemption ("IDE"), and if approved, will commence a pivotal clinical trial in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX , Dec. 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced th

      12/19/24 8:30:00 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer

      Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced changes to its executive leadership team to support its next pivotal phase of development. Effective immediately, Brad Hauser has been appointed as President and Chief Executive Officer. Additionally, Lori Bisson, former President and Chief Executive Officer, has been appointed Executive Vice Chairman

      6/17/24 4:05:00 PM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • Autonomix Appoints Jennifer Cook as Chief Business Officer

      Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer. Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated c

      3/19/24 8:45:00 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care

    $AMIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Autonomix Medical Inc.

      SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

      12/3/24 6:17:58 PM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Autonomix Medical Inc.

      SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

      11/27/24 10:15:18 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Autonomix Medical Inc.

      SC 13G - Autonomix Medical, Inc. (0001617867) (Subject)

      10/7/24 8:30:24 AM ET
      $AMIX
      Medical/Dental Instruments
      Health Care